KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Enterprise Value (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Enterprise Value data on record, last reported at -$1.3 billion in Q3 2025.

  • For Q3 2025, Enterprise Value rose 40.22% year-over-year to -$1.3 billion; the TTM value through Sep 2025 reached -$1.3 billion, up 40.22%, while the annual FY2024 figure was -$2.4 billion, 60.18% down from the prior year.
  • Enterprise Value reached -$1.3 billion in Q3 2025 per JAZZ's latest filing, down from -$1.2 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$490.8 million in Q1 2022 and bottomed at -$2.4 billion in Q4 2024.
  • Average Enterprise Value over 5 years is -$1.3 billion, with a median of -$1.3 billion recorded in 2023.
  • Peak YoY movement for Enterprise Value: plummeted 198.96% in 2021, then surged 76.6% in 2022.
  • A 5-year view of Enterprise Value shows it stood at -$591.4 million in 2021, then plummeted by 49.04% to -$881.5 million in 2022, then plummeted by 70.88% to -$1.5 billion in 2023, then plummeted by 60.18% to -$2.4 billion in 2024, then surged by 45.04% to -$1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$1.3 billion in Q3 2025, -$1.2 billion in Q2 2025, and -$1.9 billion in Q1 2025.